Review examines radiotherapy for bleeding in advanced stomach cancer
The analysis reported bleeding responses after treatment, but its dose-related findings may be affected by study limitations.
High evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
This systematic review and meta-analysis examined how often radiotherapy helped control bleeding in people with advanced stomach cancer and whether different dose-fractionation schedules were linked to different response rates. The review included studies published from 2000 through August 2026 and used statistical methods to combine results and explore dose-related patterns.
The abstract reports a pooled rebleeding rate of 32.4%. Median overall survival was 3.8 months, and median rebleeding-free survival was 3.4 months. Serious treatment-related toxicities were described as uncommon, but the review authors emphasized that the apparent benefit of higher radiation doses may largely reflect differences in which patients received those doses and other weaknesses in the underlying studies.
The question reviewed
The researchers systematically searched PubMed, Scopus, Web of Science, the Cochrane Library, and Ichushi-Web for studies published between January 2000 and August 2026. They examined palliative radiotherapy for bleeding caused by advanced gastric cancer. The main outcome was the proportion of patients whose bleeding responded to radiotherapy. A random-effects meta-analysis estimated combined response rates, while meta-regression and subgroup analyses examined whether study-level median biologically effective dose, or BED, was associated with bleeding response. The abstract does not state the number of included studies or patients.
What the review concluded
The result section appears to report a pooled bleeding-response rate of 67.5%, although the supplied abstract is missing part of the sentence and does not clearly label this value. Egger's test suggested small-study effects, meaning that smaller studies may have produced different or more favorable-looking results. Higher study-level BED was statistically associated with a greater likelihood of bleeding response in meta-regression, and higher BED categories had higher response rates in subgroup analyses. The pooled rebleeding rate was 32.4%. Median overall survival was 3.8 months, and median rebleeding-free survival was 3.4 months. Radiotherapy was generally described as well tolerated, with a low reported incidence of grade 3 or higher toxicities. These findings show associations across studies; they do not establish that a higher dose itself caused better bleeding control.
Who this is relevant to
These findings may be relevant to populations similar to those represented in the reviewed studies: people with advanced gastric cancer and cancer-related bleeding receiving palliative radiotherapy. They do not establish results for people with earlier-stage disease, other cancer types, or substantially different health conditions. Because this was a review of existing studies rather than a single controlled trial, the findings describe patterns in the available evidence and should not be read as individualized medical guidance.
Why it matters
Bleeding can be a serious complication of advanced gastric cancer, and this review summarizes how radiotherapy has been used in that setting. It provides an overview of reported bleeding control, rebleeding, survival, and serious toxicity across earlier studies. However, the short median survival and the authors' concerns about selection bias mean that the findings do not identify one universally preferable radiation schedule or establish that a higher dose is better for every patient.
Limitations & evidence assessment
The abstract does not provide the number of included studies or participants, and its reported pooled-response result is incomplete in the supplied text. The review found small-study effects, and its dose analysis used study-level rather than individual-patient data, which can produce misleading associations. Patients who received higher doses may have differed systematically from those who received lower doses, so selection bias and other methodological limitations may account for part or all of the apparent dose-response relationship. The abstract also gives limited information about differences among the included studies, follow-up duration, and how bleeding response and toxicities were measured.
Why this evidence level: Meta-analysis pooling multiple studies sits at the top of common evidence hierarchies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Japanese Journal of Radiology · 2026 · DOI: 10.1007/s11604-026-02094-3
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
